anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PURPOSE: Smoking is the single factor with the highest impact on reducing life expectancy of patients with mental illness. Patients experience difficulty in participating in smoking cessation programs but are concerned about the impact of tobacco on their health and finances. Smoking cessation advice via videoconferencing might be an alternative to an ordinary in-person consultation.
MATERIAL AND METHOD: Randomized controlled trial with follow-up at 6 months. We included patients with diagnoses of schizophrenia and affective disorder from psychiatric outpatient clinics. Intervention 1 involved daily video consultations; intervention 2 was treatment as usual.
RESULTS: Seventy patients were included. For both/all groups/interventions, rates of smoking cessation were 45% and predictors for a 50% reduction in smoking were antipsychotic medication load [odds ratio (OR) 0.54; p = 0.045] and number of nicotine patches (OR 1.02; p = 0.06). Predictors for a reduction in the number of cigarettes to < 10 were antipsychotic medication load (OR 0.52; p = 0.04), number of nicotine patches (OR 1.01; p = 0.02) and number of cigarettes at baseline [OR 0.95 (p = 0.09); adjusted OR 0.94 (p = 0.02)]. Patients prevented weight gain during the cessation period.
CONCLUSION: The smoking cessation rate was high. One of the reasons for the high cessation rate was that the intervention was carried out by highly experienced and professionally qualified staff. In addition, we used free nicotine patches to increase the patients' motivation to quit smoking. It is very important that we introduce these results into our clinical work with the patients.
The basis for the single-task training administered to the second group will be the widely used "dual-n-back training paradigm" suggested by Jaeggi et al. (2008). A complex dual n-back task including a visual and an auditory WM task will be implemented for tablet devices.
At each visit, a series of self-administered questionnaires will be used to collect demographic, behavioral risk and drug use data. In addition, data on adherence to antiretroviral therapy (ART) will be collected. Risk reduction counseling, adherence counseling, condoms \& lubricants will also be provided at these visits. Syphilis serology, Chlamydia trachomatis/Neisseria gonorrhea testing from anal and urethral compartments will be performed at baseline, month 6,12,18. HIV-positive participants, if they have not yet started ART, will be referred to preferred hospitals to receive ART regardless of CD4 count according to the 2014 National Guidelines. Drug use patterns will be longitudinally monitored prior to and after ART initiation.
To provide coated medical devices for rapidly delivering a therapeutic agent to particular tissue or body lumen and to provide methods of using the same.SOLUTION: There is provided a balloon catheter for delivering a therapeutic agent to a tissue. The balloon catheter comprises a coating layer overlying an exterior surface of the balloon. The coating layer comprises a therapeutic agent, an antioxidant, a first additive and a second additive. The therapeutic agent is chosen from rapamycin, paclitaxel, or combinations thereof. The first additive is selected from the group consisting of PEG-20 sorbitan monooleates, PEG-20 sorbitan monolaurates, PEG-15 12-hydroxy stearates, Oleth-10, Oleth-20, PEG-b-PLA, PEG-35 castor oil, and sorbitol. The second additive is selected from the group consisting of sodium dioctyl sulfosuccinate, sodium docecyl sulfates and polyvinylpyrrolidone.SELECTED DRAWING: Figure 1
An extended release dosage form and an extended release polymeric dispenser containing polymer-clay nanocomposite are provided. The polymer-clay nanocomposite contains exfoliated clay platelets dispersed in a polymer matrix. The extended release dosage form contains active ingredient in the polymer-clay nanocomposite. The extended release polymeric dispenser contains a reservoir of an active ingredient partially or completely encapsulated by a polymer-clay nanocomposite layer. Also provided are a method of providing release of an active ingredient from the extended release dosage form and a method or providing release of an active ingredient from the extended release polymeric dispenser. The extended release dosage form and the extended release polymeric dispenser are useful for the application of pharmaceutical compounds, agricultural compounds, and perfumes.
Postoperative delirium (POD) remains a common, dangerous and resource-consuming adverse event but is often preventable. The whole peri-operative team can play a key role in its management. This update to the 2017 ESAIC Guideline on the prevention of POD is evidence-based and consensus-based and considers the literature between 01 April 2015, and 28 February 2022. The search terms of the broad literature search were identical to those used in the first version of the guideline published in 2017. POD was defined in accordance with the DSM-5 criteria. POD had to be measured with a validated POD screening tool, at least once per day for at least 3 days starting in the recovery room or postanaesthesia care unit on the day of surgery or, at latest, on postoperative day 1. Recent literature confirmed the pathogenic role of surgery-induced inflammation, and this concept reinforces the positive role of multicomponent strategies aimed to reduce the surgical stress response. Although some putative precipitating risk factors are not modifiable (length of surgery, surgical site), others (such as depth of anaesthesia, appropriate analgesia and haemodynamic stability) are under the control of the anaesthesiologists. Multicomponent preoperative, intra-operative and postoperative preventive measures showed potential to reduce the incidence and duration of POD, confirming the pivotal role of a comprehensive and team-based approach to improve patients' clinical and functional status.
The study is a randomized trial to compare ART delivery through two different models: a) ART delivered through health facilities by clinically qualified staff and b) home-based care in which lay workers, i.e. non-medically qualified people, play a major role in the ART delivery and clients are followed up at health facilities less frequently. The primary objective is to measure the effects of these strategies on plasma HIV viral load. We will also examine the effects on treatment failure, disease progression, survival, adherence, family member HIV testing, sexual behavior, and cost-effectiveness.

The trial is conducted with The AIDS Support Organization (TASO) clinic in Jinja, Uganda. Randomization is conducted through geographic clusters, defined using sub-counties in the district, and stratified by distance from fixed health facilities, and urban/rural. Just over 800 participants, living in 40 clusters, will be recruited over a period of 3-6 months and followed-up over a period of 3 years.
PURPOSE:The titled pharmaceutical, containing an extract from a microalga as an active constituent, capable of developing the overall biophylactic function of the immunological and nonimmunological system, and increasing the immunological cells. CONSTITUTION:An improving agent for biophylactic function containing an extract from a microalga, e.g. alga of chlorella, genus Scenedesmus or Spirulina, as an active constituent and a diluent or another additive. The dosage form is an injection, internal medicine, external medicine, etc. The administration of the pharmaceutical increases the number of the leukocytes in blood, abdominal cavity, spleen, marrow and other immounological organs, and particularly immunological cells, e.g. lyphatic corpuscles, improves and enhances the biophylactic ability, and exhibits the expelling function of foreign bodies even after the invasion of foreign enemies and occurrence of abnormality. The extract is obtained by suspensing preferably 1-1,000g dried alga in one l water, bringing the alga into contact with the water at 50-150 deg.C for 0.5-120min, and separating the algal body by the centrifugation, etc.
Administer Verelan PM once daily at bedtime. Clinical trials studied doses of 100 mg, 200 mg, 300 mg, and 400 mg. The usual daily dose of extended-release Verelan PM in clinical trials has been 200 mg given by mouth once daily at bedtime. In rare instances, initial doses of 100 mg a day may be warranted in patients who have an increased response to verapamil [e.g. patients with impaired renal function, impaired hepatic function, elderly, low-weight patients, etc. (see Use in Specific Populations (8.5, 8.6, 8.7))]. Base upward titration on therapeutic efficacy and safety evaluated approximately 24 hours after dosing. The antihypertensive effects of Verelan PM are evident within the first week of therapy.

If an adequate response is not obtained with 200 mg of Verelan PM, the dose may be titrated upward in the following manner:

a) 300 mg each evening b) 400 mg each evening (2 × 200 mg)

When Verelan PM is administered at bedtime, office evaluation of blood pressure during morning and early afternoon hours is essentially a measure of peak effect. The usual evaluation of trough effect, which sometimes might be needed to evaluate the appropriateness of any given dose of Verelan PM, would be just prior to bedtime.
<P>PROBLEM TO BE SOLVED: To obtain a base for percutaneous absorption preparation having excellent percutaneous absorption of medicine and a skin patch preparation, in detail a base for percutaneous absorption preparation and a skin patch preparation in which the main component of the base and the kind of the medicine are widely selected.  <P>SOLUTION: The base for percutaneous absorption preparation comprises a chain alcohol that is a branched alcohol and has 10-30 total carbon atoms and 5-20 carbons of the longest straight chain. The amount of the chain alcohol contained in the base for the percutaneous absorption preparation is 15-50 wt.%. The chain alcohol is preferably a monofunctional primary chain alcohol, concretely isostearyl alcohol, hexyldecanol, octyldodecanol, etc., may be cited as the chain alcohol. Preferably an adhesive is used as the main component of the base for the percutaneous absorption preparation and the layer of the base is formed on one side of a sheetlike substrate to form the skin patch preparation.  <P>COPYRIGHT: (C)2006,JPO&NCIPI
Access to the Support-t online training and peer support platform in addition to usual diabetes care for 18 months. Support-t contains 3 components: 1) Educational material, 2) News blog and 3) Patients' discussion forum. Health care providers from the pediatric diabetes clinics will receive Support-t training and will be encouraged to recommend the Support-t platform during routine care with their patients from the active arm.
This systematic review and meta-analysis delved into the impact of race and ethnicity on outcomes following foot and ankle surgery, an area garnering increasing attention within the medical community. Despite significant literature on postsurgical clinical and functional outcomes, limited research has explored the influence of racial and ethnic factors on postoperative outcomes. In this study, data from 33 relevant studies, involving a total of 557,734 patients, were analyzed to assess outcomes across different racial and ethnic groups. Notably, only 6 studies met the criteria for inclusion in the final meta-analysis due to variations in outcome reporting. Findings revealed disparities in functional scores, pain levels, and resource utilization among different racial and ethnic cohorts. Specifically, non-White and minority patients exhibited higher rates of foot and ankle fractures and lower extremity surgeries, worse functional outcomes, increased pain, longer hospital stays, and a greater incidence of complications compared to their White counterparts. However, some studies presented contradictory results, emphasizing the necessity for further investigation to elucidate these discrepancies fully. This research underscores the importance of considering racial and ethnic factors in foot and ankle surgery outcomes and highlights the need for targeted interventions to address existing disparities.
PGD is a severe complication that affects up to 25% of lung transplant patients following surgery. Pulmonary edema, which is an abnormal build-up of fluid in the lungs, and hypoxemia, which is low blood oxygen levels, are two common symptoms that individuals with PGD experience. Treatment for this condition is often expensive, and it is the leading cause of death following lung transplant. Many potential donors and recipients are considered unsuitable for lung transplant because of concern for the development of PGD. Therefore, the ability to accurately predict which individuals are at risk for developing PGD may allow more lung transplants to be performed. Specific characteristics in both lung donors and recipients may play an important role in determining the risk of PGD. For example, genetic variations in how the body deals with harmful chemicals called oxidants may be associated with the development of PGD. The purpose of this study is to identify the specific genetic biomarkers in donors and recipients that put individuals at risk for developing PGD following a lung transplant.

This study will enroll individuals who are undergoing lung transplantation. Blood samples will be collected from lung donors and from participants prior to surgery, immediately following surgery, and 24 hours after surgery. Study researchers will monitor participants for 72 hours following surgery for symptoms of PGD. There will be no additional study visits.
1280711 Sustained release dosage forms NATIONAL PATENT DEVELOPMENT CORP 10 Oct 1969 [11 Oct 1968] 49823/69 Addition to 1205764 Heading ASB Sustained release dosage forms comprising dry compositions containing solid therapeutically-active material and a non-toxic water-insoluble hydrophilic polymer of a hydroxy C 2-3  alkyl acrylate or methacrylate or of a hydroxy C 2-3  alkoxy C 2-3  alkyl acrylate or methacrylate, are formed by casting or moulding an anhydrous casting syrup or solution comprising the therapeutically active material and the acrylate or methacrylate monomer and polymerising this monomer, resulting in a cast or moulded dosage form of inhibited deterioration or loss of potency and extended shelf life. The hydrophilic polymer is preferably a polymer of 2-hydroxyethyl acrylate or methacrylate or 2-hydroxypropyl acrylate or methacrylate. The hydrophilic polymer may be a copolymer of the acrylate or methacrylate with up to 20% of a cross-linking agent such as ethylene glycol-, propylene glycol or butylene glycoldiacrylate or -dimethacrylate. The dosage form may be administered orally or implanted subcutaneously and may be in the form of a shaped pill or tablet, the therapeutically active material comprising a central core and the polymer affording a solid outer layer surrounding the core, which may comprise an admixture of the polymer and active material. The dosage form may have an intermediate layer between the core and outer layer, e.g. the outer layer includes the same or different therapeutically-active material dispersed therethrough and the intermediate layer comprises the polymer. The therapeutically active material may be an antibiotic, sedative, hypnotic, hypotensive, vasodilator, amphetamine, hormone, vitamin, or a tranquilizer.
FIELD: genetic engineering.SUBSTANCE: invention can be used in biotechnology, medicine and agriculture for creation of gene therapy preparations. Disclosed is a gene-therapeutic DNA vector based on the VTvaf17 gene-vector DNA vector carrying the target gene, selected from a group of genes to increase the level of expression of this target gene in the human body and animals. Genotyping DNA vector VTvaf17-BDNF, or VTvaf17-VEGFA, or VTvaf17-BFGF, or VTvaf17-NGF, or VTvaf17-GDNF, or VTvaf17-NT3, or VTvaf17-CNTF, or VTvaf17-IGF1 has a nucleotide sequence SEQ ID No. 1, or SEQ ID No. 2, or SEQ ID No. 3, or SEQ ID No. 4, or SEQ ID No. 5, or SEQ ID No. 6, or SEQ ID No. 7, or SEQ ID No. 8, respectively. Also disclosed are a method of producing said vector, using a vector to increase the level of expression of target genes, an Escherichia coli strain carrying said vector, as well as a method for production of said vector on an industrial scale.EFFECT: invention provides the possibility of its safe application for genetic therapy of humans and animals.22 cl, 23 dwg, 32 ex
In this study, an 8-week multicomponent exercise program will be carried out focused on improving the general physical condition and balance of older adult subjects, in order to try to reduce the risk of falls and improve the quality of life of a group. of older adults made up of 17 participants.
Subjects randomized to the placebo group received one tablet containing baked barley powder per day (900 mg/day). placebo group consumed one capsules, three times daily before meals, for a total of three capsules consumed per day.
Acute uric acid nephropathy, which may occur after the administration of oncolytic agents, has also been reported with vincristine sulfate. In the presence of leukopenia or a complicating infection, administration of the next dose of Vincristine Sulfate Injection warrants careful consideration.

If central nervous system leukemia is diagnosed, additional agents may be required, because vincristine does not appear to cross the blood–brain barrier in adequate amounts.

Particular attention should be given to dosage and neurologic side effects if Vincristine Sulfate Injection is administered to patients with preexisting neuromuscular disease and when other drugs with neurotoxic potential are also being used.

Acute shortness of breath and severe bronchospasm have been reported following the administration of vinca alkaloids. These reactions have been encountered most frequently when the vinca alkaloid was used in combination with mitomycin–C and may require aggressive treatment, particularly when there is preexisting pulmonary dysfunction. The onset of these reactions may occur minutes to several hours after the vinca alkaloid is injected and may occur up to 2 weeks following the dose of mitomycin. Progressive dyspnea requiring chronic therapy may occur. Vincristine sulfate should not be readministered.

Care must be taken to avoid contamination of the eye with concentration of Vincristine Sulfate Injection used clinically. If accidental contamination occurs severe irritation (or, if the drug was delivered under pressure, even corneal ulceration) may result. The eye should be washed immediately and thoroughly.
In complement to actions described in the control arm, the patient's general practitioner (GP) and the patient him/herself will be contacted within 21 days of hospital discharge in order to organize an appointment between them two; this consultation is expected to take place between day 22 and day 45 after hospital discharge. If the patient does not have a GP, a health-care professional (HCP) will be provided. .GP (or HCP) will also be contacted at 6 and 13 months.
The efficacy of doxorubicin hydrochloride liposome injection in combination with bortezomib was evaluated in Trial 6, a randomized, open-label, international, multicenter study in 646 patients who had not previously received bortezomib and whose disease progressed during or after at least one prior therapy. Patients were randomized (1:1) to receive either doxorubicin hydrochloride liposome injection (30 mg/m2) administered IV on day 4 following bortezomib (1.3 mg/m2 IV on days 1, 4, 8 and 11) or bortezomib alone every 3 weeks for up to 8 cycles or until disease progression or unacceptable toxicity. Patients who maintained a response were allowed to receive further treatment. The median number of cycles in each treatment arm was 5 (range 1-18).

The baseline demographics and clinical characteristics of the patients with multiple myeloma were similar between treatment arms (Table 12).

The primary outcome measure was time to progression (TTP). TTP was defined as the time from randomization to the first occurrence of progressive disease or death due to progressive disease. The combination arm demonstrated significant improvement in TTP. As the prespecified primary objective was achieved at the interim analysis, patients in the bortezomib monotherapy group were then allowed to receive the doxorubicin hydrochloride liposome injection + bortezomib combination. Efficacy results are as shown in Table 13 and Figure 1.

Figure 1- Time to Progression Kaplan-Meier Curve

At the final analysis of survival, 78% of subjects in the doxorubicin hydrochloride liposome injection and bortezomib combination therapy group and 80% of subjects in the bortezomib monotherapy group had died after a median follow up of 8.6 years. The median survival was 33 months in the doxorubicin hydrochloride liposome injection and bortezomib combination therapy group and 31 months in the bortezomib monotherapy group. There was no difference observed in overall survival at the final analysis [HR for doxorubicin hydrochloride liposome injection + bortezomib vs. bortezomib = 0.96 (95% CI 0.80, 1.14)].

Seventy-eight percent of subjects in the doxorubicin hydrochloride liposome injection and bortezomib combination therapy group and 80% of subjects in the bortezomib monotherapy group had received subsequent therapy.
This group will receive a 1 mg rasagiline tablet to be taken once daily for one year. In addition, the following test will be performed: a Magnetic Resonance Imaging (MRI), functional Magnetic Resonance Imaging (fMRI), the Montreal Cognitive Assessment, Stroop, Digit Span, Hopkins Verbal Learning Test, Brief Test of Attention, Beck Depression Index, Hamilton Anxiety and Depression Rating Scales, Physical Function Performance Test, and Epworth Sleepiness Scale.
BACKGROUND Chronic kidney disease (CKD) is a growing global health concern. Chronic pain, as a common symptom of CKD, particularly among patients with end-stage renal disease (ESRD), is influenced by complications, dialysis procedures, and comorbidities. We aimed to evaluate chronic pain and probable neuropathic pain in 96 dialysis patients with ESRD using the Douleur Neuropathique 4 (DN4) questionnaire. MATERIAL AND METHODS A total of 96 patients from a single dialysis center were enrolled for the purpose of this study. ESRD was caused by diseases causing kidney damage, such as diabetes. The average duration of maintenance dialysis was 4.6±5.67 years. Comorbidities, functional and mental assessment, and pharmacological treatment data were collected using a questionnaire. The satisfaction with life scale was also used. Chronic pain was defined as lasting more than 3 months. The DN4 was used to determine the neuropathic component of pain. RESULTS Chronic pain was observed in 63.5% of the study participants, with 47.5% of them reporting the presence of neuropathic pain accompanied by a neuropathic component. Significantly more patients with chronic pain reported mood disorders and reduced life satisfaction, but there was no difference in their activities of daily living-assessed functional status or duration of dialysis. Patients experiencing chronic pain received non-steroidal anti-inflammatory drugs, paracetamol, and opioids. CONCLUSIONS Chronic pain, especially with a neuropathic component, is highly prevalent in patients with CKD, and its treatment remains ineffective. Undiagnosed components of pain can contribute to underdiagnosis and inadequate therapy. Further studies and staff education are needed to address this important issue.